Cost of decentralized CAR T‐cell production in an academic nonprofit setting
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Chimeric antigen receptor (CAR) T‐cell therapy is a promising immunotherapy with high acquisition costs, and it has raised concerns about affordability and sustainability in many countries. Furthermore, the current centralized production paradigm for the T cells is less than satisfactory. Therefore, several countries are exploring alternative T‐cell production modes. Our study is based on the T‐cell production experience in a nonprofit setting in Germany. We first identified the work steps and main activities in the production process. Then we determined the fixed costs and variable costs. Main cost components included personnel and technician salaries, expenditure on equipment, a clean room, as well as production materials. All costs were calculated in 2018 euros and converted into U.S. dollars. For a clean room with one machine for closed and automated manufacturing installed, annual fixed costs summed up to approximately €438 098 ($584 131). The variable cost per production was roughly €34 798 ($46 397). At the maximum capacity of one machine, total cost per product would be close to €60 000 ($78 849). As shown in the scenario analysis, if three machines were to be installed in the clean room, per production cost could be as low as €45 000 (roughly $59905). If a cheaper alternative to lentivirus was used, per production total cost could be further reduced to approximately €33 000 (roughly $44309). Decentralized T‐cell production might be a less costly and more efficient alternative to the current centralized production mode that requires a high acquisition cost.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
KTE-X19 CAR T cell therapy in relapsed or refractory mantle-cell lymphoma
Wang, M., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H., Jaglowski, S., Flinn, I. W., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914347 · Cited by 1,862
Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.
Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M. V., Turka, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817226 · Cited by 1,730
Clinical manufacturing of CAR T cells: foundation of a promising therapy
Wang, X., & Rivière, I. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.15 · Cited by 637 · cited 1×
“A closed and automated manufacturing platform can include steps from selection to harvest in a single-use, closed tubing system.(19,23) As a result, expanded T cells, with beads removed,”
MethodExploiting the curative potential of adoptive T‐cell therapy for cancer
Hinrichs, C. S., & Rosenberg, S. A. (2014) · Immunological Reviews · doi:10.1111/imr.12132 · Cited by 466 · cited 1×
“On the one hand, this therapy seems to offer high added value, given its innovative nature,(1,2) and its potential for cure.(2,40) Moreover, it has been designated as an orphan”
BackgroundMock, U., Nickolay, L., Philip, B., Cheung, G. W.-K., Zhan, H., Johnston, I. C. D., Kaiser, A. D., Peggs, K., Pule, M., Thrasher, A. J., et al. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.05.009 · Cited by 237 · cited 1×
“A closed and automated manufacturing platform can include steps from selection to harvest in a single-use, closed tubing system.(19,23) As a result, expanded T cells, with beads removed,”
MethodTisagenlecleucel — the first approved CAR-T-cell therapy: implications for payers and policy makers
Prasad, V. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.156 · Cited by 229 · cited 3×
“have expressed that this therapy with the current high price would become unaffordable in the future,(5,9-11) because of its potential to treat more cancer types.(1,10,12) Unsurprisingly, immediately upon its first marketing authorization, a question was raised about the production cost of this therapy.”
Zhu, F., Shah, N., Xu, H., Schneider, D., Orentas, R., Dropulic, B., Hari, P., & Keever-Taylor, C. A. (2018) · Cytotherapy · doi:10.1016/j.jcyt.2017.09.005 · Cited by 120
Harrison, R. P., Ruck, S., Medcalf, N., & Rafiq, Q. A. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2017.07.005 · Cited by 72 · cited 1×
“Additionally, a clean room was utilized for the production, to minimize the risk of potential batch loss due to infection.(18)”
Method
Cited by
Challenges and new technologies in adoptive cell therapy
Zhang, P., Zhang, G., & Wan, X. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01492-8 · Cited by 259
Trust in and Acceptance of Artificial Intelligence Applications in Medicine: Mixed Methods Study
Shevtsova, D., Ahmed, A., Boot, I. W. A., Sanges, C., Hudecek, M., Jacobs, J. J. L., Hort, S., & Vrijhoef, H. J. M. (2024) · JMIR Human Factors · doi:10.2196/47031 · Cited by 124
Palani, H. K., Arunachalam, A. K., Yasar, M., Venkatraman, A., Kulkarni, U., Lionel, S. A., Selvarajan, S., Korula, A., Abraham, A., George, B., et al. (2023) · Bone Marrow Transplantation · doi:10.1038/s41409-022-01866-5 · Cited by 89
Gupta, D., & Shaz, B. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06400-x · Cited by 32
“Local manufacturing should decrease patient and insurance cost, as locally manufactured products are estimated to be $80k compared to $350–500k for commercially available products, increasing patient access [17, 32].”
Sotomayor, P., Prochazka, L., & Brockhaus, M. (2022) · Pharma Research · doi:10.62655/s-epub.2022.v14.i01.pp53-62
Metadata
- Authors
- Ran, T., Eichmüller, S. B., Schmidt, P., & Schlander, M.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2020-07-06
- Volume
- 147
- Issue
- 12
- Pages
- 3438-3445
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W3034367669
- Cited by
- 110
- References
- 11
- FWCI
- 3.61
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.